Clinical Trials for Thymic Epithelial Tumors

In May - Thymic Malignancy Awareness Month, the International Thymic Malignancy Interest Group (itmig.org) organized a webinar in which some of ongoing clinical trials for thymic epithelial tumors were presented. This is the recording of the webinar.
PROGRAM:
Moderator: Chul Kim, Georgetown University, Washington, DC, USA
Presenters:
1. Meredith McAdams, National Cancer Institute, National Institutes of Health, Bethesda, USA:
- (NCT05104736) PT-112 in Subjects with Thymoma and Thymic Carcinoma
- (NCT04417660) Bintrafusp Alfa (M7824) in Subjects with Thymoma and Thymic Carcinoma
2. Dwight Owen, Ohio State University - James Comprehensive Cancer Center, Columbus, OH, USA: (NCT03463460) Pembrolizumab and Sunitinib in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
3. Chris Nabel, Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA: (NCT04262466) Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
4. Annemarie Shepherd, Memorial Sloan Kettering Cancer Center, New York, NY, USA: (NCT05354570) A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest
.
5. Q&A